Pseudouridine detection with a multiplexed epitranscriptomics test
Official title: Pseudouridine detection with single-base resolution in a multiplexed epitranscriptomics assay
Funded at Alida Biosciences, INC. · NIH-11392969 · Data updated 2026-11-12
A new multiplexed test to detect key RNA chemical markings in human samples, helping researchers study how these marks influence health and disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Alida Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | August 15, 2025 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,146,785 |
| NIH project number | 5R44GM159469-02 |
| Project ID | NIH-11392969 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to a specific patient group; the grant focuses on assay development and commercialization for research use to enable future patient-directed studies.
✕Less likely to help
Direct patient benefit is not through participation in this grant, as it centers on tool development; downstream clinical benefits may arise in the future.
What this research studies
This project aims to create a high-throughput assay that can identify multiple RNA modifications, including m6A, inosine, and pseudouridine, in a single test. By combining engineered binders with enzymatic steps, it will pull out and quantify modified RNA fragments for analysis. The goal is to provide a practical tool that researchers can use to explore the epitranscriptome’s role in cancer, neurological disorders, and viral infections, with potential to guide biomarker discovery and therapies. The work will proceed toward commercialization so that clinical and research labs can access the assay.
Why it matters
Potential benefit: If successful, patients could benefit from faster, more precise biomarker discovery and better understanding of diseases linked to RNA modifications.
How similar studies have gone: There is active interest in epitranscriptomics; this approach builds on existing knowledge but aims to provide a novel, high-throughput detection method.
Where this research is happening
-
Alida Biosciences, INC.
San Diego, United States Active
Researchers
- Principal investigator: Miles, Zachary — Alida Biosciences, INC.
- Study coordinator: Miles, Zachary
Related research
Other NIH-funded projects on the same topics.
-
Developing a platform to analyze RNA modifications
This study is working on a new tool that helps doctors and researchers better understand how tiny changes in RNA can affect health, especially in cancer, making it easier to use this information for diagnosis and treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.